Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

被引：0
|
作者：
Nielsen, Katrine Finderup [1 ,4 ]
Nielsen, Lise Birk [1 ]
Dalby, Tine [1 ]
Lomholt, Frederikke Kristensen [1 ]
Slotved, Hans-Christian [1 ]
Fuursted, Kurt [1 ]
Harboe, Zitta Barrella [1 ,2 ,3 ]
Jorgensen, Charlotte Svaerke [1 ]
Valentiner-Branth, Palle [1 ]
机构：
[1] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
[4] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen, Denmark
来源：
EMERGING INFECTIOUS DISEASES | 2024年 / 30卷 / 06期
关键词：
AGED; 65; ENGLAND; PNEUMONIA; PEOPLE; ADULTS; IMPACT; OLDER;
D O I：
10.3201/eid3006.230975
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >= 65 years of age as part of a vaccination program in Denmark during Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.
引用
收藏
页码：1164 / 1172
页数：9
相关论文
共 50 条
  • [21] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
    Masuda, Toshihiro
    Akamatsu, Taisuke
    Nakatani, Eiji
    Tamura, Kanami
    Takahashi, Shingo
    Tanaka, Yuko
    Watanabe, Hirofumi
    Endo, Yoshinari
    Suzuki, Takahito
    Noguchi, Rie
    Saigusa, Mika
    Yamamoto, Akito
    Shishido, Yuichiro
    Akita, Takefumi
    Morita, Satoru
    Asada, Kazuhiro
    Shirai, Toshihiro
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [22] Relative effectiveness of revaccination with 23-valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult Aboriginal and Torres Strait Islander people, Australia
    Takashima, Mari
    Lambert, Stephen B.
    Paynter, Stuart
    Ware, Robert S.
    VACCINE, 2019, 37 (12) : 1638 - 1641
  • [23] Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
    Wang, Yang
    Li, Jingxin
    Wang, Yuxiao
    Gu, Wei
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (04) : 1003 - 1012
  • [24] TYPE-SPECIFIC ANTIBODY-RESPONSES OF VOLUNTEERS IMMUNIZED WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE
    MUFSON, MA
    HUGHEY, D
    LYDICK, E
    JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (04): : 749 - 750
  • [25] Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Against Community-Acquired Pneumonia in the General Population Aged ≥60 Years: 3 Years of Follow-up in the CAPAMIS Study
    Ochoa-Gondar, Olga
    Vila-Corcoles, Angel
    Rodriguez-Blanco, Teresa
    Gomez-Bertomeu, Frederic
    Figuerola-Massana, Enric
    Raga-Luria, Xavier
    Hospital-Guardiola, Imma
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (07) : 909 - 917
  • [26] Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England andWales
    Djennad, Abdelmajid
    Ramsay, Mary E.
    Pebody, Richard
    Fry, Norman K.
    Sheppard, Carmen
    Ladhani, Shamez N.
    Andrews, Nick J.
    ECLINICALMEDICINE, 2018, 6 : 42 - 50
  • [27] The Efficacy of 23-Valent Pneumococcal Polysaccharide Vaccine in Preventing Pneumonia and Invasive Pneumococcal Disease in the Elderly Aged 75 Years and Older in Taiwan
    Hsieh, Meng-Jer
    Tsai, Ying-Huang
    Chang, Chee-Jen
    Wen, Yu-Wen
    Hu, Han-Chung
    Chao, Yen-Nan
    Huang, Yhu-Chering
    Yang, Cheng-Ta
    Huang, Chung-Chi
    CHEST, 2013, 144 (04)
  • [28] Cost effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany
    Jiang, Yiling
    Gauthier, Aline
    Annemans, Lieven
    van der Linden, Mark
    Nicolas-Spony, Laurence
    Bresse, Xavier
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 645 - 660
  • [29] An adult case of invasive pneumococcal disease due to serotype 12F-specific polysaccharide antibody failure following a 23-valent polysaccharide vaccination
    Tanaka, Yasuhiro
    Yamamoto, Kazuko
    Fukuda, Yuichi
    Umemura, Asuka
    Yoshida, Masataka
    Ideguchi, Shuhei
    Ashizawa, Nobuyuki
    Hirayama, Tatsuro
    Tashiro, Masato
    Takazono, Takahiro
    Imamura, Yoshifumi
    Miyazaki, Taiga
    Izumikawa, Koichi
    Yanagihara, Katsunori
    Chang, Bin
    Mukae, Hiroshi
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 2266 - 2268
  • [30] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Cornelius Remschmidt
    Thomas Harder
    Ole Wichmann
    Christian Bogdan
    Gerhard Falkenhorst
    BMC Infectious Diseases, 16
12345